The Emirates Drug Establishment (EDE) has officially granted approval for EURneffy®, a novel epinephrine-based treatment available in 1 mg and 2 mg strengths, making the UAE the first country in the region to authorise this innovative therapy.
EURneffy is the first nasal adrenaline spray indicated for the emergency treatment of severe allergic reactions in adults and children aged four years and above, with dosing determined based on body weight.
Developed by Denmark's ALK Abelló, the product introduces a significant advancement to the UAE’s healthcare and pharmaceutical landscape by enabling the administration of epinephrine via the nasal route as an alternative to injections.
This approach supports faster responses in acute allergic emergencies, where timely administration of epinephrine is critical to saving lives. It also addresses practical challenges associated with injectable treatments, including hesitation due to needle-related anxiety and difficulties in administration during critical moments.
EURneffy is designed for ease of use and rapid administration, enabling immediate intervention even by non-medically trained individuals.
